EFGARTIGIMOD ALFA for Chronic inflammatory demyelinating polyradiculoneuropathy: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 8 adverse event reports in the FDA FAERS database where EFGARTIGIMOD ALFA was used for Chronic inflammatory demyelinating polyradiculoneuropathy.
Most Reported Side Effects for EFGARTIGIMOD ALFA
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Myasthenia gravis | 46 | 18.5% | 2 | 30 |
| Off label use | 39 | 15.7% | 1 | 13 |
| Drug ineffective | 25 | 10.0% | 3 | 16 |
| Myasthenia gravis crisis | 25 | 10.0% | 0 | 16 |
| Fatigue | 22 | 8.8% | 0 | 6 |
| Pneumonia | 20 | 8.0% | 6 | 17 |
| Muscular weakness | 17 | 6.8% | 0 | 4 |
| Urinary tract infection | 17 | 6.8% | 2 | 6 |
| Malaise | 14 | 5.6% | 3 | 7 |
| Covid-19 | 13 | 5.2% | 1 | 10 |
| Dyspnoea | 13 | 5.2% | 1 | 5 |
| Headache | 13 | 5.2% | 0 | 2 |
| Therapeutic product effect incomplete | 12 | 4.8% | 0 | 7 |
| Therapy non-responder | 12 | 4.8% | 1 | 8 |
| Symptom recurrence | 11 | 4.4% | 1 | 4 |
Other Indications for EFGARTIGIMOD ALFA
Myasthenia gravis (170)
Immune thrombocytopenia (25)
Product used for unknown indication (16)
Pemphigus (9)
Muscular weakness (7)
Other Drugs Used for Chronic inflammatory demyelinating polyradiculoneuropathy
HUMAN IMMUNOGLOBULIN G (4,735)
RITUXIMAB (245)
HUMAN IMMUNOGLOBULIN G\HYALURONIDASE (88)
EFGARTIGIMOD ALFA\HYALURONIDASE-QVFC (81)
METHYLPREDNISOLONE (72)
AZATHIOPRINE (61)
MYCOPHENOLATE MOFETIL (59)
CYCLOPHOSPHAMIDE (55)
PREDNISONE (45)
BORTEZOMIB (40)